Shots:

• Lilly to acquire Disarm for $135M upfront and ~$1.225B as potential development regulatory and commercial milestones- making a total deal value of ~1.36B
• The acquisition will expand Lilly's R&D efforts in pain and neurodegeneration with the addition of Disarm's preclinical SARM1 programs for axonal degeneration
• Disarm is advancing its potent SARM1 inhibitors in preclinical development intending to deliver patients with peripheral neuropathy and other neurological diseases like ALS and MS
  
   ­ Ref: Eli Lilly | Image: Eli Lilly